Enliven Therapeutics (ELVN) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.49

Estimate

-$0.36

Surprise

-37.4%

Score today

5.6/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Enliven Therapeutics (ELVN) reported a wider loss than forecast — adjusted EPS of -$0.49 against the -$0.36 estimate (a 37.4% shortfall).

TrendMatrix currently rates ELVN Sell at 5.6/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -37.4% surprise compares with a +1.9% four-quarter average. Next scheduled report: 2026-11-11.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$49.45

Price target

$64.29

Stop

$46.97

Upside to target

+30.0%

Reward-to-risk

3.3:1

Model outputs from TrendMatrix’s engine as of 2026-09-21 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$3.62B

P/E (fwd)

-21.1

52-week range

$14.79–$62.32

Off 52-week high

20.7%

RSI (14)

21

Volume vs avg

4.56×

Score today

5.6/10